Lantheus (LNTH) Revenue & Revenue Breakdown
Lantheus Revenue Highlights
Latest Revenue (Y)
$1.30B
Latest Revenue (Q)
$394.09M
Main Segment (Y)
Product
Main Geography (Y)
US Segment
Lantheus Revenue by Period
Lantheus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.30B | 38.65% |
| 2022-12-31 | $935.06M | 119.91% |
| 2021-12-31 | $425.21M | 25.28% |
| 2020-12-31 | $339.41M | -2.28% |
| 2019-12-31 | $347.34M | 1.15% |
| 2018-12-31 | $343.37M | 3.62% |
| 2017-12-31 | $331.38M | 9.78% |
| 2016-12-31 | $301.85M | 2.86% |
| 2015-12-31 | $293.46M | -2.70% |
| 2014-12-31 | $301.60M | 6.32% |
| 2013-12-31 | $283.67M | -1.54% |
| 2012-12-31 | $288.11M | -19.14% |
| 2011-12-31 | $356.29M | - |
Lantheus generated $1.30B in revenue during NA 2023, up 38.65% compared to the previous quarter, and up 377.56% compared to the same period a year ago.
Lantheus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $394.09M | 6.52% |
| 2024-03-31 | $369.98M | 4.51% |
| 2023-12-31 | $354.00M | 10.64% |
| 2023-09-30 | $319.95M | -0.55% |
| 2023-06-30 | $321.70M | 6.95% |
| 2023-03-31 | $300.78M | 14.29% |
| 2022-12-31 | $263.17M | 9.98% |
| 2022-09-30 | $239.29M | 6.96% |
| 2022-06-30 | $223.72M | 7.11% |
| 2022-03-31 | $208.88M | 61.22% |
| 2021-12-31 | $129.56M | 26.93% |
| 2021-09-30 | $102.07M | 1.00% |
| 2021-06-30 | $101.06M | 9.25% |
| 2021-03-31 | $92.51M | -1.75% |
| 2020-12-31 | $94.15M | 6.33% |
| 2020-09-30 | $88.54M | 34.14% |
| 2020-06-30 | $66.01M | -27.22% |
| 2020-03-31 | $90.70M | 1.52% |
| 2019-12-31 | $89.35M | 4.16% |
| 2019-09-30 | $85.78M | 0.08% |
| 2019-06-30 | $85.70M | -0.93% |
| 2019-03-31 | $86.51M | 0.28% |
| 2018-12-31 | $86.27M | -2.96% |
| 2018-09-30 | $88.90M | 3.89% |
| 2018-06-30 | $85.57M | 3.56% |
| 2018-03-31 | $82.63M | 1.71% |
| 2017-12-31 | $81.24M | 1.63% |
| 2017-09-30 | $79.94M | -10.01% |
| 2017-06-30 | $88.84M | 9.19% |
| 2017-03-31 | $81.36M | 9.43% |
| 2016-12-31 | $74.35M | 1.76% |
| 2016-09-30 | $73.06M | -6.29% |
| 2016-06-30 | $77.97M | 1.95% |
| 2016-03-31 | $76.47M | 7.41% |
| 2015-12-31 | $71.20M | -3.94% |
| 2015-09-30 | $74.12M | 1.10% |
| 2015-06-30 | $73.31M | -2.02% |
| 2015-03-31 | $74.82M | -2.79% |
| 2014-12-31 | $76.97M | 1.70% |
| 2014-09-30 | $75.68M | 0.09% |
| 2014-06-30 | $75.61M | 3.10% |
| 2014-03-31 | $73.34M | 2.33% |
| 2013-12-31 | $71.67M | 1.82% |
| 2013-09-30 | $70.39M | -0.31% |
| 2013-06-30 | $70.60M | -0.59% |
| 2013-03-31 | $71.02M | - |
Lantheus generated $394.09M in revenue during Q2 2024, up 6.52% compared to the previous quarter, and up 131.02% compared to the same period a year ago.
Lantheus Revenue Breakdown
Lantheus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Strategic Partnerships And Other | $51.88M | $46.87M | $25.30M | - | - |
| DEFINITY | $279.77M | $244.99M | $232.76M | - | - |
| License and Royalty Revenues | $33.36M | $48.02M | $24.85M | - | - |
| Other Precision Diagnostics | $22.98M | $22.82M | $26.97M | - | - |
| Techne Lite | $87.37M | $88.86M | $91.29M | - | - |
| Total Precision Diagnostics | $390.12M | $356.68M | $351.02M | - | - |
| Other Radiopharmaceutical Oncology | $3.13M | $4.10M | $5.47M | - | - |
| PYLARIFY | $851.30M | $527.40M | $43.41M | - | - |
| Product | $1.26B | - | - | - | - |
| Radiopharmaceutical Oncology | $854.43M | $531.51M | $48.89M | - | - |
| Product Revenue, Net | - | $887.04M | $400.36M | - | - |
| International Segment | - | - | - | $44.61M | $43.35M |
| US Segment | - | - | - | $294.80M | $303.99M |
Lantheus's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (32.91%), Radiopharmaceutical Oncology (22.27%), PYLARIFY (22.18%), Total Precision Diagnostics (10.17%), DEFINITY (7.29%), Techne Lite (2.28%), Strategic Partnerships And Other (1.35%), License and Royalty Revenues (0.87%), Other Precision Diagnostics (0.60%), and Other Radiopharmaceutical Oncology (0.08%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Techne Lite | $28.19M | $21.71M | $23.27M | $21.59M | $20.99M | $24.73M | $22.09M | $19.44M | $22.61M | $22.04M | $22.68M | $23.77M | $22.80M | - | - | - | - | - | - | - |
| Product | $392.76M | $369.31M | $319.51M | $314.08M | $292.26M | $233.37M | $217.78M | $180.01M | $96.68M | $93.56M | $87.32M | - | - | - | - | - | - | - | - | - |
| PYLARIFY | $273.25M | $258.87M | $215.43M | $210.52M | $195.47M | $160.64M | $143.75M | $130.23M | $92.78M | - | - | - | - | - | - | - | - | - | - | - |
| Other Radiopharmaceutical Oncology | - | $384.00K | $848.00K | $818.00K | $717.00K | $919.00K | $928.00K | $928.00K | $1.33M | - | - | - | - | - | - | - | - | - | - | - |
| License and Royalty Revenues | $1.33M | $662.00K | $438.00K | $7.62M | $8.53M | $7.29M | $5.93M | $5.94M | $28.87M | $6.76M | $5.39M | $7.50M | $5.19M | - | - | - | - | - | - | - |
| Total Precision Diagnostics | $112.11M | $104.21M | $96.35M | $97.58M | $95.62M | $94.37M | $89.01M | $87.11M | $86.20M | $87.04M | $87.88M | $90.36M | $85.75M | - | - | - | - | - | - | - |
| Strategic Partnerships And Other | $8.72M | $6.51M | $7.32M | $12.78M | $8.98M | $7.24M | $5.60M | $5.45M | $28.58M | $6.84M | $5.30M | $7.90M | $5.25M | - | - | - | - | - | - | - |
| Radiopharmaceutical Oncology | $273.25M | $259.25M | $216.28M | $211.34M | $196.19M | $161.56M | $144.68M | $131.16M | $94.10M | $35.68M | $8.89M | $2.81M | $1.50M | - | - | - | - | - | - | - |
| Other Precision Diagnostics | $5.83M | $5.93M | $5.74M | $5.45M | $5.81M | $6.02M | $6.17M | $5.36M | $5.26M | $5.68M | $7.56M | $6.74M | $6.98M | - | - | - | - | - | - | - |
| DEFINITY | $78.10M | $76.56M | $67.34M | $70.53M | $68.82M | $63.62M | $60.74M | $62.31M | $58.33M | $59.31M | $57.64M | $59.84M | $55.97M | - | - | - | - | - | - | - |
| International Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.97M | $11.07M | $8.61M | $11.96M | $10.63M | $11.13M | $10.52M |
| US Segment | - | - | - | - | - | - | - | - | - | - | - | - | - | $81.18M | $77.47M | $57.40M | $78.75M | $78.72M | $74.65M | $75.19M |
Lantheus's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (33.47%), PYLARIFY (23.28%), Radiopharmaceutical Oncology (23.28%), Total Precision Diagnostics (9.55%), DEFINITY (6.66%), Techne Lite (2.40%), Strategic Partnerships And Other (0.74%), Other Precision Diagnostics (0.50%), and License and Royalty Revenues (0.11%).
Lantheus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| US Segment | $294.80M | $72.53M | - |
| Worldwide | - | $347.34M | - |
| UNITED STATES | - | - | $288.58M |
| All Other | - | - | $54.79M |
Lantheus's latest annual revenue breakdown by geography, as of Dec 20: US Segment (100.00%).
Quarterly Revenue by Country
| Country | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US Segment | $81.18M | $77.47M | $57.40M | $19.36M | $78.72M | $74.65M | $75.19M | $75.43M | $72.75M | $70.25M | $74.09M | $71.49M |
Lantheus's latest quarterly revenue breakdown by geography, as of Dec 20: US Segment (100.00%).
Lantheus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| CTLT | Catalent | $4.38B | $1.07B |
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| LNTH | Lantheus | $1.30B | $394.09M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| DERM | Journey Medical | $79.18M | $14.86M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
LNTH Revenue FAQ
What is Lantheus’s yearly revenue?
Lantheus's yearly revenue for 2023 was $1.3B, representing an increase of 38.65% compared to 2022. The company's yearly revenue for 2022 was $935.06M, representing an increase of 119.91% compared to 2021. LNTH's yearly revenue for 2021 was $425.21M, representing an increase of 25.28% compared to 2020.
What is Lantheus’s quarterly revenue?
Lantheus's quarterly revenue for Q2 2024 was $394.09M, a 6.52% increase from the previous quarter (Q1 2024), and a 22.50% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $369.98M, a 4.51% increase from the previous quarter (Q4 2023), and a 23.00% increase year-over-year (Q1 2023). LNTH's quarterly revenue for Q4 2023 was $354M, a 10.64% increase from the previous quarter (Q3 2023), and a 34.52% increase year-over-year (Q4 2022).
What is Lantheus’s revenue growth rate?
Lantheus's revenue growth rate for the last 3 years (2021-2023) was 204.89%, and for the last 5 years (2019-2023) was 273.25%.
What are Lantheus’s revenue streams?
Lantheus's revenue streams in c 23 are Strategic Partnerships And Other, DEFINITY, License and Royalty Revenues, Other Precision Diagnostics, Techne Lite, Total Precision Diagnostics, Other Radiopharmaceutical Oncology, PYLARIFY, Product, and Radiopharmaceutical Oncology. Strategic Partnerships And Other generated $51.88M in revenue, accounting 1.35% of the company's total revenue, up 10.68% year-over-year. DEFINITY generated $279.77M in revenue, accounting 7.29% of the company's total revenue, up 14.19% year-over-year. License and Royalty Revenues generated $33.36M in revenue, accounting 0.87% of the company's total revenue, down -30.53% year-over-year. Other Precision Diagnostics generated $22.98M in revenue, accounting 0.60% of the company's total revenue, up 0.68% year-over-year. Techne Lite generated $87.37M in revenue, accounting 2.28% of the company's total revenue, down -1.68% year-over-year. Total Precision Diagnostics generated $390.12M in revenue, accounting 10.17% of the company's total revenue, up 9.37% year-over-year. Other Radiopharmaceutical Oncology generated $3.13M in revenue, accounting 0.08% of the company's total revenue, down -23.70% year-over-year. PYLARIFY generated $851.3M in revenue, accounting 22.18% of the company's total revenue, up 61.41% year-over-year. Product generated $1.26B in revenue, accounting 32.91% of the company's total revenue Radiopharmaceutical Oncology generated $854.43M in revenue, accounting 22.27% of the company's total revenue, up 60.76% year-over-year.
What is Lantheus’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Lantheus was Product. This segment made a revenue of $1.26B, representing 32.91% of the company's total revenue.